FDA extends comment period to Aug. 8 on regulating additional tobacco products that meet definition of a tobacco product; products under review include e-cigarettes, cigars, pipe tobacco

Nevin Barich

Nevin Barich

SILVER SPRING, Maryland , July 15, 2014 (press release) – On April 25, 2014, FDA published a proposed rule, Tobacco Products Deemed To Be Subject to the Food, Drug & Cosmetic Act (Deeming), to regulate additional tobacco products that meet the definition of a tobacco product. Proposed newly deemed products would include e-cigarettes, cigars, pipe tobacco, certain dissolvables that are not “smokeless tobacco,” gels, and waterpipe tobacco.

Recently, we extended the comment period for the proposed rule to August 8, 2014. We understand there may be some confusion surrounding how to submit comments.

Here’s all you need to know:

You can comment on the proposed rule by visiting the open docket.

CTP has also created a web page dedicated to the proposed rule where you can find a host of resources, including a snapshot of the issue, a feature on currently regulated and proposed deemed tobacco products, and the full text of the proposed rule.

Learn more and submit your comments before August 8.

FDA Issues Draft Guidance on SE Report Requests

Today, FDA published draft guidance titled “Substantial Equivalence Reports: Manufacturer Requests for Extensions or to Change the Predicate Tobacco Product” in the Federal Register. Once finalized, this draft guidance will represent FDA’s current thinking on manufacturer requests for:

Extensions of time to respond to CTP-identified deficiencies in Substantial Equivalence (SE) reports; and

Change of predicate tobacco products in submitted SE reports.

During the review of an SE report, CTP may issue a scientific advice/information letter or preliminary finding letter to a manufacturer describing deficiencies of the SE report. In response to those letters, some manufacturers have requested an extension of time to respond to the deficiencies, or have requested to change the predicate tobacco product identified in the SE report. This draft guidance states that CTP will no longer grant extensions, except in very limited instances. Because CTP no longer has a backlog of regular SE reports awaiting review, and CTP is starting review on regular SE reports as they are received, there is no longer a delay when manufacturers withdraw their application and resubmit it when they have gathered the appropriate information.

Additionally, this draft guidance states that, because the comparison of the new and predicate products is the basis for the determination of substantial equivalence, manufacturers should not change the predicate tobacco product once scientific review begins.

Beginning today, comments regarding this draft guidance may be submitted for 60 days at Regulations.gov. CTP also plans to post a webinar discussing this draft guidance on its website soon. A link will be sent out in This Week in CTP when it is posted.

To learn more about the SE process, please visit our Substantial Equivalence webpage.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

Share:

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.